ALOPECIA AREATA

This study follows 487 adults with alopecia areata who are starting Litfulo (ritlecitinib) for the first time. Researchers will monitor side effects and measure hair regrowth using the SALT score, aiming for a score of 20 or less (meaning 80% or more scalp hair coverage). The goa…

This study looks at the long-term safety and effectiveness of a drug called CTP-543 for adults with moderate to severe alopecia areata, a condition that causes patchy hair loss. About 1,000 people who already completed 24 weeks of treatment in a prior CTP-543 trial will continue …

This study tests an experimental drug called amlitelimab for adults with severe alopecia areata, a condition causing significant hair loss. About 166 participants will receive either the drug or a placebo as a shot under the skin for 36 weeks. The goal is to see if the drug can s…

This study tests a new drug called bempikibart (ADX-914) for people with severe alopecia areata, a condition causing significant hair loss. The trial involves 75 adults aged 18-75 with at least 50% scalp hair loss. Researchers are measuring how much hair regrows over 24 to 36 wee…

This study tests two doses (50 mg and 100 mg) of the medicine ritlecitinib, taken once daily, for severe alopecia areata—a condition causing significant hair loss on the scalp, face, and body. About 550 people aged 12 and older with at least 50% scalp hair loss will be randomly a…

This study tests an experimental drug called rezpegaldesleukin in 94 adults with severe to very severe alopecia areata, a condition causing significant hair loss. Participants receive either the drug or a placebo for 36 weeks, with an optional extension. The main goal is to measu…

This study looks at whether adding vitamin D3 cream to a skin-pricking treatment (microneedling) helps hair grow back better in people with patchy hair loss (alopecia areata). Eighty adults will get either microneedling alone or microneedling plus vitamin D3 every two weeks for s…

This study examines how patients with severe alopecia areata (an autoimmune disease causing hair loss) are using ritlecitinib in real-world clinics, not just in controlled trials. Researchers will look at medical records of about 300 people aged 12 and older who started the drug …

This study is creating a large registry of 15,000 adults and children with inflammatory skin conditions like eczema, psoriasis, and vitiligo. Researchers will follow participants in regular clinics to see how well current and new treatments work and what side effects occur. The g…

This observational study looks at whether certain blood markers (VEGF-A and VCAM-1) are different in people with alopecia areata compared to healthy individuals. Researchers will also check for changes in tiny blood vessels at the nail base and link these to hair loss severity. A…